Redeye provides a research update following the Q2 report published by Alzinova earlier
today. The company reported an increased cash burn as it intensifies its preparations
ahead of the upcoming phase II study. The company has now selected a qualified CRO and
submitted an IND for the trial as it continues to look for a financing solution for the study,
preferably through a licensing deal for ALZ-101. We reiterate our fair value range (SEK1 –
SEK10) with a base case valuation of SEK5.
LÄS MER
